HNSPF
Hansoh Pharmaceutical Group Co Limited/ADR
- PER (TTM)
- 32.06
- PER (Forward)
- -
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 5.20
- 시가총액
- 27.22B
- 배당수익률
- 123.00%
- 베타
- 0.55
- 1개월 수익률
- -13.00%
- 3개월 수익률
- -8.39%
- 6개월 수익률
- -10.22%
- 1년 수익률
- 63.23%
- 2년 수익률
- -
- 5일 평균거래량
- 0
- 60일 평균거래량
- 196
- 1년 평균거래량
- 153
- 5d/60d 거래량 비율
- 0.00×
- 60d/1y 거래량 비율
- 1.28×
- 변동성(60일, 연환산)
- 38.84%
- BB 스퀴즈 스코어
- 1.48
- SMA50 비율
- 0.90
- SMA200 비율
- 0.94
- RSI (14)
- 15
- 20일 수렴도
- 0.07
- 52주 최고
- 5.16
- 52주 최저
- 2.48
- 고점 대비
- -13.00%
- 저점 대비
- 81.36%
펀더멘털 갱신: 2026-05-10T09:24:26+00:00 · 시세 갱신: 2026-05-10T06:40:53+00:00
회사 정보
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited operates as a subsidiary of Stellar Infinity Company Ltd.